Liquidia Corporation

LQDA Healthcare Drug Manufacturers Specialty & Generic

Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.

Revenue
+1,842.7%
EPS
+271.4%
Free cash flow
+270.2%
Total debt
−9.04%

Quarter to June 2026, against a year earlier

44.69 2.69 −5.68%
Market cap
$4.0B
P/E
28.5×
Fwd P/E
22.1×
Dividend yield
—
F-score
5/9
Altman Z
4.08
Beneish M
6.79
Dividend safety
n/a

Liquidia Corporation (LQDA) Gross margin

Alert me on Gross margin

Liquidia Corporation's gross margin over the twelve months to 30 June 2026 was 92.5%, up 0.9 percentage points from fiscal 2025 (91.6%). Over the past ten years it has ranged from −342.0% (fiscal 2020) to 95.6% (fiscal 2017); the current reading is higher than 81% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 53.5% and above the Healthcare sector median of 53.9%.

Gross margin, annual

Embed this chart

Annual newest first

Period Gross margin Change (points)
FY2025 91.6% 33.64
FY2024 58.0% (25.49)
FY2023 83.5% 1.43
FY2022 82.1% 11.03
FY2022 71.0% (5.45)
FY2021 76.5% 23.06
FY2021 53.4% (14.44)
FY2020 67.9% 409.82
FY2020 −342.0% (431.96)
FY2019 90.0% 34.60

Quarterly newest first

Period Gross margin Change (points)
Jun 2026 93.3% 2.19
Mar 2026 91.1% (1.25)
Dec 2025 92.3% (1.83)
Sep 2025 94.2% 11.10
30 more quarters

Against its own ten years

Low −342.0% High 95.6%
Ten-year median 79.3%
Current reading's percentile 88

Gross margin against peers

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on LQDA